161 related articles for article (PubMed ID: 37229458)
1. The clinical and genetic features in patients coexisting primary breast and thyroid cancers.
Fu J; He M; Wu Q; Zhang X; Qi X; Shen K; Wang X; Zhang G
Front Endocrinol (Lausanne); 2023; 14():1136120. PubMed ID: 37229458
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological features, survival and risk in breast cancer survivors with thyroid cancer: an analysis of the SEER database.
Li S; Yang J; Shen Y; Zhao X; Zhang L; Wang B; Li P; Wang Y; Yi M; Yang J
BMC Public Health; 2019 Nov; 19(1):1592. PubMed ID: 31783815
[TBL] [Abstract][Full Text] [Related]
3. A Possible Association Between Thyroid Cancer and Breast Cancer.
An JH; Hwangbo Y; Ahn HY; Keam B; Lee KE; Han W; Park DJ; Park IA; Noh DY; Youn YK; Cho BY; Im SA; Park YJ
Thyroid; 2015 Dec; 25(12):1330-8. PubMed ID: 26442580
[TBL] [Abstract][Full Text] [Related]
4. The co-occurrence of both breast- and differentiated thyroid cancer: incidence, association and clinical implications for daily practice.
Piek MW; de Boer JP; van Duijnhoven F; van der Wal JE; Vriens M; van Leeuwaarde RS; van der Ploeg IMC
BMC Cancer; 2022 Sep; 22(1):1018. PubMed ID: 36163009
[TBL] [Abstract][Full Text] [Related]
5. Association between breast cancer and thyroid cancer: A study based on 13Â 978 patients with breast cancer.
Huang NS; Chen XX; Wei WJ; Mo M; Chen JY; Ma B; Yang SW; Xu WB; Wu J; Ji QH; Guo XM; Liu GY; Shao ZM; Wang Y
Cancer Med; 2018 Dec; 7(12):6393-6400. PubMed ID: 30480382
[TBL] [Abstract][Full Text] [Related]
6. Cysteine conjugate beta-lyase 2 (CCBL2) expression as a prognostic marker of survival in breast cancer patients.
Meng X; Wang L; He M; Yang Z; Jiao Y; Hu Y; Wang K
PLoS One; 2022; 17(6):e0269998. PubMed ID: 35771747
[TBL] [Abstract][Full Text] [Related]
7. Characteristics and survival of patients with metachronous or synchronous double primary malignancies: breast and thyroid cancer.
Zhang L; Wu Y; Liu F; Fu L; Tong Z
Oncotarget; 2016 Aug; 7(32):52450-52459. PubMed ID: 27223440
[TBL] [Abstract][Full Text] [Related]
8. Survival Outcomes in Thyroid Cancer Patients with Co-Occurring Breast Cancer: Evidence of Mortality Risk Attenuation.
Baumgarten MW; Goemann IM; Scheffel RS; Maia AL
Clin Breast Cancer; 2024 Apr; ():. PubMed ID: 38670860
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer prognosis is better in patients who develop subsequent metachronous thyroid cancer.
Lei K; He X; Yu L; Ni C; Chen H; Guan D; Sun K; Zou H
PLoS One; 2019; 14(5):e0215948. PubMed ID: 31042767
[TBL] [Abstract][Full Text] [Related]
10. Thyrotropin suppression therapy using levothyroxine does not negatively affect breast cancer prognosis.
He X; Zhong M; Zhang Q; Aierken N; Cui L; Xing Z; Lei K
Cancer Treat Res Commun; 2022; 31():100525. PubMed ID: 35114502
[TBL] [Abstract][Full Text] [Related]
11. Increased expression of thyroid hormone receptor alpha and estrogen receptor alpha in breast cancer associated with thyroid cancer.
Kim YA; Kim YA; Cho SW; Song YS; Min HS; Park IA; Park DJ; Hwang KT; Park YJ
Eur J Surg Oncol; 2021 Jun; 47(6):1316-1323. PubMed ID: 33558123
[TBL] [Abstract][Full Text] [Related]
12. Decreased breast cancer-specific mortality risk in patients with a history of thyroid cancer.
Cheng W; Shen X; Xing M
PLoS One; 2019; 14(10):e0221093. PubMed ID: 31644578
[TBL] [Abstract][Full Text] [Related]
13. Unbalanced bidirectional causal association between thyroid cancer and ER-positive breast cancer: should we recommend screening for thyroid cancer in breast cancer patients?
Wang H; Li S; Shi J; Feng C; Wang Y; Zhang F
BMC Genomics; 2023 Dec; 24(1):762. PubMed ID: 38082224
[TBL] [Abstract][Full Text] [Related]
14. Cartilage oligomeric matrix protein acts as a molecular biomarker in multiple cancer types.
Guo B; Wang Y; Liu W; Zhang S
Clin Transl Oncol; 2023 Feb; 25(2):535-554. PubMed ID: 36255654
[TBL] [Abstract][Full Text] [Related]
15. [Clinical characteristics and prognostic analysis of double primary breast cancer and thyroid cancer].
Zhai J; Kong XY; Fang Y; Wang J
Zhonghua Zhong Liu Za Zhi; 2021 Dec; 43(12):1287-1291. PubMed ID: 34915638
[No Abstract] [Full Text] [Related]
16. Increased prevalence of breast cancer among patients with thyroid and parathyroid disease.
Garner CN; Ganetzky R; Brainard J; Hammel JP; Berber E; Siperstein AE; Milas M
Surgery; 2007 Dec; 142(6):806-13; discussion 813.e1-3. PubMed ID: 18063060
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of LncRNA HOTAIR is Associated with Poor Prognosis in Thyroid Carcinoma: A Study Based on TCGA and GEO Data.
Li HM; Yang H; Wen DY; Luo YH; Liang CY; Pan DH; Ma W; Chen G; He Y; Chen JQ
Horm Metab Res; 2017 May; 49(5):388-399. PubMed ID: 28351094
[TBL] [Abstract][Full Text] [Related]
18. The Clinicopathological Significance and Correlative Signaling Pathways of an Autophagy-Related Gene, Ambra1, in Breast Cancer: a Study of 25 Microarray RNA-Seq Datasets and in-House Gene Silencing.
He RQ; Xiong DD; Ma J; Hu XH; Chen G; Sun WL
Cell Physiol Biochem; 2018; 51(3):1027-1040. PubMed ID: 30476925
[TBL] [Abstract][Full Text] [Related]
19. Spatiotemporal Co-existence of Female Thyroid and Breast Cancers in Hangzhou, China.
Fei X; Christakos G; Lou Z; Ren Y; Liu Q; Wu J
Sci Rep; 2016 Jun; 6():28524. PubMed ID: 27341638
[TBL] [Abstract][Full Text] [Related]
20. Establishment and validation of an aging-related risk signature associated with prognosis and tumor immune microenvironment in breast cancer.
Wang Z; Liu H; Gong Y; Cheng Y
Eur J Med Res; 2022 Dec; 27(1):317. PubMed ID: 36581948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
